A 24-week, randomized, double-blind, active-controlled, parallel group trial to assess the superiority of oral linagliptin and metformin compared to linagliptin monotherapy in newly diagnosed, treatmentnaïve, uncontrolled Type 2 Diabetes Mellitus patients.

Register Today!

Let others know about this Trial!

Trial Information

Trial Duration24 weeks
Number of Visits10
Lead CRCJason Collin

For additional information
on this trial contact: